Immunosuppression in hepatitis C virus-infected patients after kidney transplantation

Contributions to Nephrology

Volumn 176, Issue , 2012, Pages 97-107

  Manuel, Oriol ^a   Baid Agrawal, Seema ^b   Moradpour, Darius ^a   Pascual, Manuel ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CHRONIC KIDNEY FAILURE; GRAFT SURVIVAL; HEPATITIS C; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; METHODOLOGY;

GRAFT SURVIVAL; HEPATITIS C; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION;

EID: 84856812320     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000332387     Document Type: Article

References (49)

1. Shepard CW, Finelli L, Alter MJ: Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-567. (Pubitemid 41196755)
2. Baid-Agrawal S, Pascual M, Moradpour D, Frei U, Tolkoff-Rubin N: Hepatitis C virus infection in haemodialysis and kidney trans-plant patients. Rev Med Virol 2008;18:97-115. (Pubitemid 351428341)
3. Bloom RD, Sayer G, Fa K, Constantinescu S, Abt P, Reddy KR: Outcome of hepatitis C virus-infected kidney transplant candi-dates who remain on the waiting list. Am J Transplant 2005;5:139-144. (Pubitemid 40095138)
4. Roth D, Gaynor JJ, Reddy KR, et al: Effect of kidney transplantation on outcomes among patients with hepatitis C. J Am Soc Nephrol 2011;22:1152-1160.
5. Baid-Agrawal S, Farris AB, Pascual M, et al: Overlapping pathways to transplant glomerulopathy: chronic humoral rejec-tion, hepatitis C infection and thrombotic microangiopathy Kidney Int 2011, Epub ahead of print.
6. Baid S, Cosimi AB, Tolkoff-Rubin N, Colvin RB, Williams W W, Pascual M: Renal disease associated with hepatitis C infec-tion after kidney and liver transplantation. Transplantation 2000;70:255-261. (Pubitemid 30602737)
7. Genesca J, Vila J, Cordoba J, et al: Hepatitis C virus infection in renal transplant recipients: epidemiology clinical impact, serological confirmation and viral replication. J Hepatol 1995;22:272-277.
8. Kliem V, van den Hoff U, Brunkhorst R, et al: The long-term course of hepatitis C after kidney transplantation. Transplantation 1996;62:1417-1421. (Pubitemid 26404662)
9. Roth D, Zucker K, Cirocco R, et al: A pro-spective study of hepatitis C virus infection in renal allograft recipients. Transplantation 1996;61:886-889. (Pubitemid 26107422)
10. Bouthot BA, Murthy BV, Schmid CH, Levey AS, Pereira BJ: Long-term follow-up of hepatitis C virus infection among organ transplant recipients: implications for poli-cies on organ procurement. Transplantation 1997;63:849-853. (Pubitemid 27150592)
11. Forman JP Tolkoff-Rubin N, Pascual M, Lin J: Hepatitis C, acute humoral rejection, and renal allograft survival. J Am Soc Nephrol 2004;15:3249-3255. (Pubitemid 39578858)
12. Mathurin P Mouquet C, Poynard T, et al: Impact of hepatitis B and C virus on kid-ney transplantation outcome. Hepatology 1999;29:257-263. (Pubitemid 29024011)
13. Meier-Kriesche HU, Ojo AO, Hanson JA, Kaplan B: Hepatitis C antibody status and outcomes in renal transplant recipients. Transplantation 2001;72:241-244. (Pubitemid 32729342)
14. Morales JM, Dominguez-Gil B, Sanz-Guajardo D, Fernandez J, Escuin F: The influence of hepatitis B and hepatitis C virus infection in the recipient on late renal allograft failure. Nephrol Dial Transplant 2004;19(suppl 3):iii72-iii76. (Pubitemid 38961443)
15. Scott DR, Wong JK, Spicer TS, et al: Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand. Transplantation 2010;90:1165-1171.
16. Legendre C, Garrigue V, Le BC, et al: Harmful long-term impact of hepatitis C virus infection in kidney transplant recipi-ents. Transplantation 1998;65:667-670. (Pubitemid 28128936)
17. Fabrizi F, Martin P Dixit V, Bunnapradist S, Dulai G: Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 2005;5:1452-1461. (Pubitemid 40839438)
18. Cruzado JM, Carrera M, Torras J, Grinyo JM: Hepatitis C virus infection and de novo glomerular lesions in renal allografts. Am J Transplant 2001;1:171-178. (Pubitemid 33674158)
19. Somsouk M, Lauer GM, Casson D, et al: Spontaneous resolution of chronic hepatitis C virus disease after withdrawal of immunosuppression. Gastroenterology 2003;124:1946-1949. (Pubitemid 36666789)
20. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC: Tacrolimus versus ciclosporin as primary immunosuppres-sion for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005;331:810.
21. Baid S, Tolkoff-Rubin N, Farrell ML, et al: Tacrolimus-associated posttransplant dia-betes mellitus in renal transplant recipients: role of hepatitis C infection. Transplant Proc 2002;34:1771-1773.
22. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K: Cyclosporin A sup-presses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003;38:1282-1288. (Pubitemid 37314838)
23. Kahraman A, Witzke O, Scherag A, et al: Impact of immunosuppressive therapy on hepatitis C infection after renal transplanta-tion. Clin Nephrol 2011;75:16-25.
24. Luan FL, Schaubel DE, Zhang H, et al: Impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C. Transplantation 2008;85:1601-1606.
25. Berenguer M, Royuela A, Zamora J: Immunosuppression with calcineurin inhibi-tors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007;13:21-29. (Pubitemid 46099970)
26. Irish W, Arcona S, Bowers D, Trotter JF: Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN Database. Am J Transplant 2011;11:1676-1685.
27. ReViS-TC Study Group: Cyclosporine a-based immunosuppression reduces relapse rate after antiviral therapy in trans-planted patients with hepatitis C virus infection: a large multicenter cohort study. Transplantation 2011;92:334-340.
28. Berenguer M, Prieto M, Cordoba J, et al: Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treat-ment of rejection. J Hepatol 1998;28:756-763. (Pubitemid 28223478)
29. Berenguer M, Aguilera V, Prieto M, et al: Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006;44:717-722.
30. Humar A, Crotteau S, Gruessner A, et al: Steroid minimization in liver transplant recipients: impact on hepatitis C recurrence and post-transplant diabetes. Clin Transplant 2007;21:526-531. (Pubitemid 47161831)
31. Akalin E, Murphy B, Sehgal V, Ames S, Daly L, Bromberg JS: Rapid steroid withdrawal in hepatitis C virus-positive kidney transplant recipients. Clin Transplant 2004;18:384-389. (Pubitemid 39077071)
32. Rostaing L, Izopet J, Sandres K, Cisterne JM, Puel J, Durand D: Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil. Transplantation 2000;69:991-994. (Pubitemid 30174134)
33. Manzia TM, Angelico R, Toti L, et al: Long-term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C. Transpl Int 2011;24:461-468.
34. Berenguer M, Crippin J, Gish R, et al: A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003;38:34-41. (Pubitemid 36775793)
35. Burak KW, Kremers WK, Batts KP, et al: Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002;8:362-369. (Pubitemid 34467371)
36. Zhu J, Wu J, Frizell E, et al: Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology 1999;117:1198-1204. (Pubitemid 29512680)
37. Gallego R, Henriquez F, Oliva E, et al: Switching to sirolimus in renal transplant recipients with hepatitis C virus: a safe option. Transplant Proc 2009;41:2334-2336.
38. Asthana S, Toso C, Meeberg G, et al: The impact of sirolimus on hepatitis C recur-rence after liver transplantation. Can J Gastroenterol 2011;25:28-34.
39. Wagner D, Kniepeiss D, Schaffellner S, et al: Sirolimus has a potential to influent viral recurrence in HCV positive liver trans-plant candidates. Int Immunopharmacol 2010;10:990-993.
40. Rosen HR, Shackleton CR, Higa L, et al: Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997;92:1453-1457. (Pubitemid 27412863)
41. Rodrigues A, Pinho L, Lobato L, et al: Hepatitis C virus genotypes and the influ-ence of the induction of immunosuppression with anti-thymocyte globulin (ATG) on chronic hepatitis in renal graft recipients. Transpl Int 1998;11(suppl 1):S115-S118. (Pubitemid 128683522)
42. Nair S, Loss GE, Cohen AJ, Eason JD: Induction with rabbit antithymocyte globu-lin versus induction with corticosteroids in liver transplantation: impact on recurrent hepatitis C virus infection. Transplantation 2006;81:620-622.
43. Kamar N, Borde JS, Sandres-Saune K, et al: Induction therapy with either anti-CD25 monoclonal antibodies or rabbit antithymo-cyte globulins in liver transplantation for hepatitis C. Clin Transplant 2005;19:83-89. (Pubitemid 40227857)
44. Uemura T, Schaefer E, Hollenbeak CS, Khan A, Kadry Z: Outcome of induction immuno-suppression for liver transplantation compar-ing anti-thymocyte globulin, daclizumab, and corticosteroid. Transpl Int 2011;24:640-650.
45. Moonka DK, Kim D, Kapke A, Brown KA, Yoshida A: The influence of induction ther-apy on graft and patient survival in patients with and without hepatitis C after liver trans-plantation. Am J Transplant 2010;10:590-601.
46. Ennishi D, Maeda Y, Niitsu N, et al: Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multi-center analysis. Blood 2010;116:5119-5125.
47. Kamar N, Sandres-Saune K, Rostaing L: Influence of rituximab therapy on hepatitis C virus RNA concentration in kidney-transplant patients. Am J Transplant 2007;7:2440. (Pubitemid 47347866)
48. Mahajan TD, Hooker R, Maher L, Brown G, Reimold A: Abatacept therapy for rheu-matoid arthritis in the setting of hepatitis C infection. J Clin Rheumatol 2010;16:332-334.
49. Marcos A, Eghtesad B, Fung JJ, et al: Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation 2004;78:966-971. (Pubitemid 39391856)